The purpose of this trial is to determine the efficacy and safety of an investigational drug in patients with type 2 diabetes mellitus.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
363
sitagliptin phosphate 25 mg, 50 mg, 100 mg QD, or 200 mg QD 12-weeks.
placebo QD 12-weeks
Change From Baseline in HbA1c at Week 12
HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the Week 0 HbA1c percent.
Time frame: Baseline and Week 12
Change From Baseline in Glycosylated Albumin at Week 12
Change from baseline at Week 12 is defined as Week 12 minus Week 0.
Time frame: Baseline and Week 12
Change From Baseline in Fasting Plasma Glucose at Week 12
Change from baseline at Week 12 is defined as Week 12 minus Week 0.
Time frame: Baseline and Week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.